Cancer classification using the Immunoscore: a worldwide task forceCybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity.The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networksTrial WatchImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerTrial Watch: Adoptive cell transfer for oncological indicationsBioinformatics for cancer immunology and immunotherapyTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyThe continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signaturesTrial Watch:: Oncolytic viruses for cancer therapyTrial watch: Dendritic cell-based anticancer therapyTowards the introduction of the 'Immunoscore' in the classification of malignant tumoursTrial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyTrial Watch-Oncolytic viruses and cancer therapyTrial Watch-Immunostimulation with cytokines in cancer therapyFrom mice to humans: developments in cancer immunoeditingHierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activationType, density, and location of immune cells within human colorectal tumors predict clinical outcome31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneThe immune contexture in human tumours: impact on clinical outcomeData integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction.Soluble CD16 in plasma cell dyscrasias.Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions.Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy.Immunosurveillance in human non-viral cancers.Trial Watch: Toll-like receptor agonists in oncological indications.Trial watch: Immunostimulatory cytokines in cancer therapy.TNFRSF1A mutations and autoinflammatory syndromes.Effector memory T cells, early metastasis, and survival in colorectal cancer.Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.Trial Watch: Peptide-based anticancer vaccines.CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico dataTumor immunosurveillance in human cancers.Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.Glucocorticoid-inducible genes that regulate T-cell function.Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference.
P50
Q21245495-06ACBBAF-C3B0-425D-A379-311B7308D44FQ24292375-986D8432-93D4-417B-8833-98029874E2C5Q24535763-13E922C2-2895-41A1-9C61-1906BDD8D058Q24570122-D71DBCFC-67B4-462C-9B06-37ADD14507C5Q24618653-39F2306F-3BB3-43E4-8638-788EA1A0A469Q26765115-82087D40-7CD1-4A12-B979-3BB36411CB12Q26780387-F320CA38-0CA8-4752-9B82-6A1C116E429CQ26785545-963291A9-52E7-4150-9DEC-445C22599F5EQ26864876-7A0F0897-5DD5-466E-BCA1-C30FAA8D260CQ26993238-69D2CDF7-AAD8-469C-A4EF-07020A1A6384Q26996518-8506FD0A-319C-46E5-84B3-14120F4AFBCFQ27004011-9B7E76F0-5B20-459E-B231-28A7B6320B41Q27015137-B50F63D5-8347-40D0-A7F3-779BB2E49131Q27021951-BCE47914-35C1-4F5A-9DFC-5D28762C87A5Q27024047-ED3B461A-F239-452D-B108-70E5080D6C99Q27026489-C3ABCACD-A607-4EF1-A7B6-4EAF614FBCA3Q28067939-C4180B23-79F7-438A-8140-7E279CB4C77CQ28072347-EFE6A18D-FB1C-4F1F-A820-D45242771E08Q28078725-4F3EF393-AB23-4792-8BB5-1BE86F4A253EQ28088304-900DE3EF-0AED-4D6C-AC8C-B3EDFDA1175BQ28115484-90A3B1CD-ED80-4865-8282-F71A96D905D4Q28131662-DAC191BC-B719-4A00-835C-439B9240A1F0Q28553703-207139ED-53A2-470F-AEBF-9EB230B4F893Q29620667-DE175CB6-2782-4B7B-915D-7C4BD50527C2Q33531525-BF9AED7B-18D0-4221-B658-BFB333A0A725Q33536889-24FE3AC6-3247-4AB8-8C7F-037F0FCD589DQ33682312-72594B5A-6E59-40CE-9513-502B6925242FQ33690193-B4CD6C4B-516B-4DA1-8F4C-0C92E2A2029FQ33794202-F242882A-A7B2-4627-955D-F9490C2662DBQ33878578-04985A73-3708-4F2A-B71E-06B1A75E2652Q33880165-C0572BFC-F444-490A-8B6B-B7E54CCF13A0Q33971049-C3265E5F-A5BB-4CFA-B72F-B4B2B6300E2AQ33992461-52C0609C-89EE-4358-A0D0-09F3A309FA19Q34335039-E76381E1-28E0-41D7-9401-6E8A4497D573Q34483345-7E6F0F8E-6CDE-4BF0-9A23-8A80032542C4Q34550500-4233C8DD-8A80-4744-8FA4-E87AFEE683AAQ34601529-8C9B15A3-DF64-4D59-827B-FDF7E8B9C0D7Q34825919-B7528418-0BC2-4383-A0A4-042A530AD7ADQ34923546-CA56DB5A-F5BF-4E11-87F4-9C6A09F71322Q35132245-50942C25-D478-4C79-9DE1-FC61F408A3E3
P50
description
Frans bioloog
@nl
French biologist
@en
ahli biologi asal Perancis
@id
biologiste français
@fr
biologo francese
@it
biologo frantziarra
@eu
bitheolaí Francach
@ga
biòleg francès
@ca
biólogo francés
@es
biólogo francés
@gl
name
Jérôme Galon
@ace
Jérôme Galon
@ast
Jérôme Galon
@ca
Jérôme Galon
@da
Jérôme Galon
@de
Jérôme Galon
@en
Jérôme Galon
@es
Jérôme Galon
@fr
Jérôme Galon
@hu
Jérôme Galon
@id
type
label
Jérôme Galon
@ace
Jérôme Galon
@ast
Jérôme Galon
@ca
Jérôme Galon
@da
Jérôme Galon
@de
Jérôme Galon
@en
Jérôme Galon
@es
Jérôme Galon
@fr
Jérôme Galon
@hu
Jérôme Galon
@id
altLabel
Jerome Galon
@en
Jerome Galon
@nl
prefLabel
Jérôme Galon
@ace
Jérôme Galon
@ast
Jérôme Galon
@ca
Jérôme Galon
@da
Jérôme Galon
@de
Jérôme Galon
@en
Jérôme Galon
@es
Jérôme Galon
@fr
Jérôme Galon
@hu
Jérôme Galon
@id
P214
P101
P106
P19
P21
P214
P27
P2798
P31
P4124
jerome-galon_68062
P496
0000-0001-9635-1339
P569
1967-02-06T00:00:00Z
P735
P7859
viaf-192975354